Esophagomediastinal fistula during durvalumab plus tremelimumab with chemotherapy in angiotensin-converting enzyme 2-positive non-small cell lung cancer: a case report
Clinicians should be aware that COVID-19 might be associated with the development of severe irAEs and unexpectedly enhanced antitumor effects. The findings also suggest new fields of study regarding the interaction between viral infection and tumor immune response, which may inform future therapeutic approaches.
Authors
- Yuji Sakuma (ORCID: https://orcid.org/0000-0003-2298-1359)
- Hirofumi Chiba (ORCID: https://orcid.org/0000-0002-7033-3084)
- Toshiyuki Sumi (ORCID: https://orcid.org/0000-0002-2540-5878)
- Keigo Matsuura
- Takumi Ikeda (ORCID: https://orcid.org/0000-0003-0527-3078)
- Kotomi Arioka
- Miki Yamaguchi (ORCID: https://orcid.org/0000-0002-6897-697X)
- Yuichi Yamada
- Taiki Ishigooka
Institutions
- Sapporo Medical University (JP)
- Hakodate National Hospital (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-444
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.29